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Abstract
Background: To compare the results of external beam radiotherapy in combination with 3D- computed
tomography (CT)-implanted interstitial high dose rate brachytherapy (ERT/3D-HDR-BT) versus conventional external
beam radiotherapy (ERT) for the treatment of stage T2b nasopharyngeal carcinoma (NPC).
Methods: Forty NPC patients diagnosed with stage T2b NPC were treated with ERT/3D-HDR-BT under local
anesthesia. These patients received a mean dose of 60 Gy, followed by 12-20 Gy administered by 3D-HDR-BT.
Another 101 patients diagnosed with non-metastatic T2b NPC received a mean dose of 68 Gy by ERT alone during
the same period.
Results: Patients treated with ERT/3D-HDR-BT versus ERT alone exhibited an improvement in their 5-y local failure-
free survival rate (97.5% vs. 80.2%, P = 0.012) and disease-free survival rate (92.5% vs. 73.3%, P = 0.014). Using
multivariate analysis, administration of 3D-HDR-BT was found to be favorable for local control (P = 0.046) and was
statistically significant for disease-free survival (P = 0.021). The incidence rate of acute and chronic complications
between the two groups was also compared.
Conclusions: It is possible that the treatment modality enhances local control due to improved conformal dose
distributions and the escalated radiation dose applied.
Introduction
In 1996, Chua et al. [1] reported the incidence of para-
pharyngeal extension in NPC patients to be as high as
72.5%. Of these patients, 65.5% exhibited extensions into
the prestyloid space and/or the masticator space, which
was associated with lower rates of 5-year local control
and distant metastasis-free survival. Numerous studies
also showed that parapharyngeal extension was an unfa-
vorable prognosis factor in predicting overall relapse,
local relapse, and distant metastasis [2-4].
Over the past few decades, two-dimensional bra-
chytherapy (2D-BT) has been used to apply high doses
of radiation directly to the primary tumor, while sparing
nearby critical normal tissues. Some studies have
reported that brachytherapy significantly enhances local
control and the overall survival rate for early T-stage
NPC [5,6], but 2D-BT may provide less adequate target
volume coverage if the tumor has extended into the
parapharyngeal space. 3D-computed tomography (CT)-
implanted interstitial HDR brachytherapy (3D-HDR-BT)
was developed from 2D-BT techniques [7-9], and with
this approach, the target volume, as well as all of the
vital structures involved, can be outlined using Plato
software (PLATO BPS 14.2, Nucletron B.V, Veenendaal,
The Netherlands). Reconstruction and 3D planning of
interstitial implants with non-parallel applicators also
use Plato software, as well as a real-time evaluation of
the isodose distribution achieved in all CT slices.
Accordingly, this interstitial implantation technique has
been applied to the treatment of prostate cancer [10,11],
breast cancer [12], rectal carcinoma [13], and cervical
cancer [14]. However, there are no reports of the treat-
ment results achieved using 3D-HDR-BT for the treat-
ment of NPC.
Therefore, the goal of this current study is to evaluate
the local control and distant metastasis events exhibited
by stage T2b NPC patients that received ERT with or
without additional 3D-HDR-BT therapy.
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Patient characteristics
Forty NPC patients diagnosed with stage T2b disease at
the Cancer Center of Sun Yat-Sen University (Guangz-
hou, People’s Republic of China) between January 2004
and February 2008 were prescribed ERT with 3D-HDR-
BT. To evaluate the efficacy of this treatment modality,
these 40 cases were retrospectively compared with 101
patients diagnosed with non-metastatic T2b disease that
were treated with ERT alone during the same period.
For the two patient groups, the male/female ratio was
about 3:1 with 104 males and 37 females, and the med-
ian age was 44 years (range, 19-80 years). Histological
examination showed that 97.2% of the patients had
World Health Organization (WHO) type II or III dis-
ease, 4 patients had type I disease.
Each patient was confirmed by biopsy, direct fiber-
optic examination, complete blood count, blood chemis-
try test, chest X-ray, bone scan, and the extension of
disease was further evaluated by physical examination,
magnetic resonance imaging (MRI) of the nasopharynx
and neck. Gross disease was carefully diagrammed for
each patient and all MRI materials and clinical records
were reviewed to minimize heterogeneity in restaging.
Two radiologists specializing in head-and-neck cancers
evaluated all scans and any disagreements were resolved
by consensus. All stage T2b patients were restaged
according to the American Joint Committee on Cancer
staging system (6
th edition) [15]. Acute and late compli-
cations were scored according to criteria of the Radia-
tion Therapy Oncology Group (RTOG) scoring system.
Treatment methods
All patients were treated with definitive intent radiation
therapy, and the external beam radiotherapy techniques
have previously been reported [16]. After completion of
primary radiotherapy, fiber optic nasopharyngoscopy
was performed to assess tumor response. In the event of
documented persistent or relapse disease, salvage treat-
ments were provided, including brachytherapy, naso-
pharyngectomy or stereotactic radiotherapy (SRT).
For the ERT/3D-HDR-BT group, 40 patients received
ERT followed by 3D-HDR-BT. Patients were immobi-
lized in the supine position with a thermoplastic mask
and treated with two lateral-opposing faciocervical por-
tals to irradiate the nasopharynx and upper neck in one
volume, followed by application of the shrinking-field
technique to limit irradiation of the spinal cord. An
anterior cervical field was used to treat the neck with a
laryngeal block. The primary nasopharynx tumor
received 60 Gy of ERT. Overall, the neck region received
an accumulated radiation dose of 50 Gy, while the
involved areas of the neck received 60-62 Gy. All
patients were treated with one fraction daily for 5 days
per week.
3D-CT-based interstitial brachytherapy was delivered
using a high-dose-rate (HDR) afterloading machine
(microSelectron, Nucletron,V e e n e n d a a l ,T h eN e t h e r -
lands), with
192-Ir as the source and ProGuide Needle
(189.601 ProGuide Needle Set 6F, sharp) used as the
nasopharyngeal applicator (microSelectron, Nucletron,
nylon tube technique) (Figure 1). Patients were immobi-
lized in the supine position with a thermoplastic mask
and administered local anesthesia. The fiberoptic endo-
scope was guided to the treatment sites via the inferior
meatus to the treatment positions. The interstitial por-
tion of the implant consisted of inserting 2-4 stationary
ProGuide Sharp Needles in the parapharyngeal tissues
of the primary tumor site followed by immobilization of
the applicators. The 3D treatment plan was performed
as follows: 1) ProGuide Sharp Needles with an appropri-
ate length for interstitial treatment were placed into the
treatment volume, with the needles immobilized using
the button sewed into the wings of the nose; 2) CT
scanning using a 0.2 cm step to obtain 0.2 cm thick
slices was performed after placement of the implants
and CT images were subsequently transferred to a 3D
treatment planning system (PLATO PBS 14.2); 3) the
target volume (i.e. the nasopharyngeal primary tumor
area and the parapharyngeal involved site) and ProGuide
Sharp Needles were contoured; 4) non-parallel needles
were reconstructed using the catheter reconstruction
Figure 1 A ProGuide Needle (189.601 ProGuide Needle Set 6F,
sharp) was used as a nasopharyngeal applicator
(microSelectron, Nucletron, nylon tube technique) for stage
T2b NPC patients.
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plan was performed, so that any displacement of the
needles could be identified and maintained within 1
mm;. 5) With all volumes defined, dwell positions were
automatically activated within the target volume. Dose
points were placed on the target surface and the pre-
scribed reference dose was calculated from the mean
dose achieved over all of the specified dose points on
the target surface. Isodose surfaces, the dose homogene-
ity index, and coverage of the target volume by prescrip-
tion dose were calculated and evaluated (Figure 2). All
patients received 16GY over the entire implant volume.
Following treatment, applicator components were
removed from the patients as follows: 1) applicators
were disconnected from the indexer and flexible transfer
tube; 2) needles were gently removed using standard
interstitial techniques; 3) needles were discarded and the
obturators were appropriately cleaned.
For the ERT alone group, 101 patients received radio-
therapy delivered by a linear accelerator with 6 or 8 MV
photons using the same ERT techniques. Primary naso-
pharynx tumors received a mean radiation dose of 68
Gy (range, 66-70 Gy), and all patients received 1 fraction
daily for 5 days per week. During the period of ERT, all
the patients were performed fiber optically every week
to assess the tumor response to treatment.
Patients with AJCC-2002 N2-3 lymph nodal involved
d i s e a s e( 1 9i nt h eE R T / 3 D - H D R - B Tg r o u pa n d4 3i n
the ERT group) received neoadjuvant, concomitant, or
adjuvant chemotherapy (all cisplatin-based).
Statistical analysis
All survival rates were calculated from the date of histo-
logical diagnosis using SPSS version 13.0 (SPSS, Inc.,
Chicago, IL). The following endpoints (interval to the
first defining event) were assessed: local failure-free sur-
vival (LFFS), nodal failure-free survival (NFFS), overall
survival (OS), disease-free survival (DFS), distant metas-
tasis-free survival (DMFS), and disease-specific survival
(DSS). The chi-square test was used to compare clinical-
pathological characteristics between the two groups.
Estimates of actuarial survival rates were based on the
method of Kaplan-Meier [17]. The log-rank test was
used to compare survival curves [18], while multivariate
analyses were performed using the Cox proportional
hazards model [19]. A P-value ≤ 0.05 was considered
statistically significant.
Methods
Forty NPC patients with stage T2b NPC were treated
with ERT/3D-HDR-BT under local anesthesia. These
patients received 60 Gy of ERT, followed by 16 Gy
administered by 3D-HDR-BT. Another 101 patients
received a mean dose of 68 Gy by ERT alone during
the same period. The median age, gender, AJCC stage,
N-category, histological grade, and chemotherapy
treatment regimen for the ERT/3D-HDR-BT group
and the ERT group were not significantly different
(Table 1).
Local and regional control
One patient in the combined treatment group and 20
patients in the ERT group developed a local recurrence.
The 5-year actuarial LFFS rates for the ERT/3D-HDR-
BT group and the ERT group were 97.5% and 80.2%,
respectively (P = 0.012). For local control, the additional
3D-HDR-BT therapy received by patients was found to
be significant according to the log-rank test (Figure 3).
Two patients in the ERT/3D-HDR-BT group and 1
patient in the ERT group experienced recurrence of
neck nodal, and the 5-year actuarial NFFS rate for each
of the treatment groups was 99.0% and 95.0%, respec-
tively (P = 0.141). Furthermore, the local regional survi-
val rate was 92.5% and 79.2%, respectively, for the two
treatment groups (P = 0.066).
Survival rates
The 5-year actuarial OS, DFS, DMFS, and DSS curves
for the ERT/3D-HDR-BT group versus the ERT group
are shown in Figure 4 a-d. The specific survival rates
were 97.5% and 91.1% (P = 0.231), 92.5% and 73.3% (P
= 0.014), 97.5% and 92.1% (P = 0.301), and 97.5% and
Figure 2 Axial CT image of a NPC patient with stage T2b
disease showing four ProGuide Sharp Needles in the
parapharyngeal space with 2.5 GY, 2.25 GY, 2.0 GY, 1.75 GY,
1.50 GY, and 1.25 GY isodose lines.
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rate was significantly different for the two groups. There
was no trend of improvement observed for the other
endpoints between the two groups.
Multivariate analyses
Potential prognostic factors, including gender, age (≤ 45
y vs. > 45 y), N-stage (0-3), and treatment factor
(administration of 3D-HDR-BT), were included in a Cox
proportional hazards model with backward elimination
of the insignificant explanatory variables. The results of
t h em u l t i v a r i a t ea n a l y s i sw e r es u m m a r i z e di nT a b l e2 ,
and administration of 3D-HDR-BT was identified as a
favorable prognostic factor for LFFS, the ERT/3D-HDR-
BT group was found to have lower hazard rates of LFFS
than the ERT group (Cox regression: P =0 . 0 4 6 ,R R=
0.129, 95% CI: 0.017 - 0.968). When all of the potential
prognostic factors associated with 3D-HDR-BT were
fitted into the Cox model, the parameter estimate of the
administration of 3D-HDR-BT changed by only 2%, and
3D-HDR-BT remained the only significant prognostic
factor for determining the ultimate LFFS rate. The Cox
proportional hazard analysis also showed that adminis-
tration of 3D-HDR-BT was a favorable prognostic factor
for DFS (Cox regression: P = 0.021, RR = 0.181, 95% CI:
0.042-0.774). In contrast, N-category was found to be an
unfavorable prognostic variable for the endpoints of OS,
DMFS, and DSS.
Complications
All 40 patients in the ERT/3D-HDR-BT group experi-
enced small amounts of blood loss, which was success-
fully managed with conservative treatment measures so
that none of the patients required blood-transfusions
during the course of treatment. Overall, treatment-
related complications were generally controlled within
the two different treatment groups. Of the patients with
N-stage (N2-3) disease in the two groups that were trea-
ted with concurrent chemo-radiotherapy (DDP 40 mg/
m
2 per week), 9 patients experienced Radiation Therapy
Oncology Group (RTOG) grade III-IV hematological
toxicity, 11 patients experienced grade III mucositis, and
no cases of severe epistaxis required blood transfusions.
The most common radiation-related complication was
xerostomia. Various degrees of xerostomia were seen
commonly, and 37 patients developed xerostomia during
their course of radiotherapy ,8o fw h i c hw e r ef r o mt h e
ERT/3D-HDR-BT group. Other side effects experienced
included different grades of hearing impairment (n =
35), with 5 patients experiencing grade 1/2 hearing
impairment in the ERT/3D-HDR-BT group, and 1
patient undergoing a complete loss of hearing (i.e. grade
4) in the ERT group. One patient in the ERT group
developed a limited ability to open their mouth (2.5
cm), and incidences of pituitary-endocrine dysfunction,
neck fibrosis limiting movement, temporal lobe necrosis,
and cranial nerve palsy were not seen for patients in the
two groups. In addition, no significant late toxicities
directly due to the implantation interstitial technique
Figure 3 Five-year actuarial local failure-free survival (LFFS)
curves for ERT/3D-HDR-BT vs. ERT groups.
Table 1 Characteristics of 141 NPC patients at
presentation
Patient Characteristics ERT/3D-HDR-BT n (%) ERT n (%) P-value
Age (years) 0.743
≤ 45 23 (57.5%) 55 (54.5%)
> 45 17 (42.5%) 46 (45.5%)
Gender 0.252
Male 34 (85.0%) 77 (76.2%)
Female 6 (15.0%) 24 (23.8%)
Histology 0.956
WHO type I 1 (2.5%) 3 (3.00%)
WHO type II/III 39 (97.5%) 98 (97.0%)
UICC stage 0.064
II 32 (80.0%) 89 (88.1%)
III 6 (15.0%) 12 (11.9%)
IV a 2 (5.0%) 0 (0%)
N stage 0.282
N0-1 21 (52.5%) 58 (57.4%)
N2 17 (42.5%) 43 (42.6%)
N3 2 (5.0%) 0
Therapy 0.264
Received 19 (78.4%) 43 (81.4%)
Not received 21 (14.9%) 58 (1.5%)
WHO: World Health Organization; UICC: International Union Against Cancer.
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ulceration/necrosis were identified for 7 patients in the
ERT/3D-HDR-BT group exhibiting foul-smelling crust,
and for 19 patients in the ERT group exhibiting light to
middle ulceration/necrosis.
Discussion
T h er o l eo fr o u t i n ei n t r a c a v i t yb r a c h y t h e r a p yf o rT 2 b
NPC patients at initial diagnosis remains controversial
[6,20-23]. Some oncologists consider the dose
distribution achieved with routine brachytherapy to be
far from optimal when the parapharyngeal space is
involved, especially for cases of advanced parapharyngeal
invasion [24]. In 2005, Leung et al. [25] reported excel-
lent local control for 34 NPC patients with T2b disease
that received routine brachytherapy. In addition, there
have been many improvements in imaging technology
and treatment techniques, particularly with the develop-
ment of 3D-HDR-BT from 2D-BT. In this study, we ret-
rospectively analyzed the treatment results for stage T2b
Figure 4 Five-year actuarial survival curves for patients treated with ERT/3D-HDR-BT vs. ERT: (a) overall survival (OS); (b) disease-free
survival (DFS); (c) distant metastasis-free survival (DMFS); and disease-specific survival (DSS).
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ERT alone.
In a comparison of the treatment results for the two
patient groups, a 17.3% absolute improvement in local
control rate was identified for the 3D-HDR-BT group.
This contributed to an overall improvement in the 5-year
LFFS rate for the ERT/3D-HDR-BT group that was also
accompanied by an acceptable level of acute and late treat-
ment-related toxicity. We hypothesized that this rate of
improvement was due to more efficient conformal dose
distributions and the escalation of radiation dose that
was able to be achieved with ERT/3D-HDR-BT. This
hypothesis was supported by evidence of a dose-response
relationship for NPC that was found to be greater than the
conventional tumoricidal level previously achieved [26-28].
These results were consistent with other studies, where
ERT/3D-HDR-BT had been shown to gain excellent local
control and increase survival rates for patients with pros-
tate cancer [10,11], breast cancer [12], locally advanced
rectal carcinoma [13], and cervical cancer [14]. Given the
rapid fall-off in radiation that is characteristic of treatment
with
192-Ir, 3D-HDR-BT provides the opportunity to
increase the radiation dose directly administered to the
nasopharyngeal mucosa and the parapharyngeal space.
In this study, one patient in the 3D-HDR-BT group
developed local recurrence. Given that the dose distribu-
tion of 3D-HDR-BT is able to cover the target volume
for the patients with parapharyngeal space involvement,
and the observation that tumor recurrence is within the
primary gross tumor site, the possibility that a region of
tumor will not receive radiation is little with this techni-
que. Therefore, we hypothesize that local failures that
do occur despite these considerations, are a result of
intrinsic radioresistance of the tumor. In this study,
the ERT/3D-HDR-BT combined treatment modality
achieved a high probability of local control while limit-
ing radiation dose to normal structures, thereby demon-
strating that patients with non-metastatic stage T2b
NPC can be effectively treated with the 3D-HDR-BT
implantation interstitial technique. Furthermore, these
results contribute to our understanding of the benefits
of treating T2b tumors with 3D-HDR-BT.
Compared with the ERT group, an improvement in
DFS was achieved with 3D-HDR-BT, and this was statis-
tically significant for stage T2b patients. According to
multivariate analyses, administration of 3D-HDR-BT
was associated with a significantly lower disease failure
rate. Therefore, since the administration of 3D-HDR-BT
did not reduce either nodal or distant failure rates, the
improvement in the 5-year DFS is hypothesized to be
the result of a reduction in local failure.
Two patients in the ERT/3D-HDR-BT group and one
patient in the ERT group experienced neck nodal recur-
rences, indicating that treatment with 3D-HDR-BT did
not improve regional nodal control rates. However, both
groups achieved excellent regional control due to the
biological characteristic of metastasis neck nodes which
have been reported to be radiocurable [29]. Previously,
Yeh et al.[ 2 0 ]r e p o r t e dt h a te l e c t i v ei r r a d i a t i o no fa l l
cervical lymphatics should be performed. However,
while all node-negative patients received at least 46.8 Gy
of elective neck irradiation, only 1.2% developed regional
relapse.
Compared with the ERT group, patients of the ERT/
3D-HDR-BT group did not show improvements in their
rates of OS, DMFS, and DSS. All patients with N2-3
category tumors received chemotherapy-radiotherapy of
DDP at 40 mg/m
2 per week, and benefits were asso-
ciated with the administration of chemotherapy for
locally advanced NPC. In a previous study, adjunct che-
motherapy was found to further provide significantly
higher local regional control and survival rates [30],
while other studies showed an overall survival benefit
Table 2 Summary of multivariate analysis of prognostic
factors
Endpoint Factors B P-value Exp(B) 95% CI
LFFS UICC stage NS
N stage NS
3D-HDR-BT:
no vs. yes
-2.048 0.046 0.129 0.017-0.968
Chemotherapy NS
NFFS UICC stage NS
N stage NS
3D-BT:
no vs. yes
NS
Chemotherapy NS
OS UICC stage 7.979 0.005 4.729 1.609-13.898
N stage NS
3D-HDR-BT:
no vs. yes
NS
Chemotherapy NS
DFS UICC stage NS
N stage NS
3D-HDR-BT:
no vs. yes
-1.709 0.021 0.181 0.042-0.774
Chemotherapy NS
DSS UICC stage NS
N stage 1.428 0.016 4.168 1.307-13.299
3D-HDR-BT:
no vs. yes
NS
Chemotherapy NS
DMFS UICC stage NS
N stage 1.436 0.015 4.205 1.322-13.378
3D-HDR-BT:
no vs. yes
NS
Chemotherapy NS
UICC: International Union Against Cancer; NS: not significant; CI: confidence
interval.
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adjuvant chemotherapy [31,32]. In this study, no
improvement in patient survival was observed for either
treatment group, although the relatively short patient
f o l l o w - u pi n t e r v a lm a yh a v eh a dar o l ei nt h i so b s e r v a -
tion. Further studies will be needed with longer follow-
up periods in order to confirm the treatment results of
this study.
The interstitial implantation procedure was found to
be well tolerated by all of the T2b patients that received
ERT/3D-HDR-BT. While some patients did experience
small amounts of blood loss over the course of the
interstitial implantation procedure, epistaxis was mana-
ged with conservative treatment measures and was
always self-limiting. None of the patients required
blood-transfusions due to excessive bleeding during the
course of treatment.
In the ERT group, one patient presented with limited
mouth opening, and this case emphasizes the impor-
tance of a thorough anamnesis and examination in
order to discover such phenomena as early as possible.
For cases with this condition, treatment should be
restricted to palliative dental treatment, excluding any
surgical procedure.
The most common radiation-related complication
experienced was xerostomia. The incidence rate of xer-
ostomia was found to differ significantly between the
two treatments groups, probably due to the rapid dose
falloff associated with ERT/3D-HDR-BT that could
achieve a high probability of local control while limiting
the exposure of normal vital tissues to the radiation
dose. Furthermore, patients treated with ERT/3D-HDR-
BT did not report any major complications or any sig-
nificant late toxicity directly due to the implantation
procedure.
Despite the improvement in patient treatment that can
be also achieved using 3D techniques, the availability of
this technology is limited in many countries. However,
the accessibility of afterloading machines, coupled with
a relatively simple procedure, makes brachytherapy an
attractive technique for centers that do not have three-
dimensional facilities, or that have tight machine times,
as is often the case in developing countries. Novel radio-
therapy treatment equipment used for intensity-modu-
lated radiation therapy (IMRT), image-guided radiation
therapy (IGRT), and three-dimensional conformal radia-
tion therapy (3D-CRT), all have been shown to achieve
excellent local control and survival outcomes in the
treatment of patients with early stage T NPC. However,
the cost of these novel technologies is very high [33-35].
When treatment costs were analyzed at our institution,
ERT/3D-HDR-BT was found to reduce personnel cost
while still provide good treatment results.
Our study was limited by the non-randomized treat-
ment performed due to the retrospective approach of
our study. However, disease characteristics and para-
meters were comparable between the two groups ana-
lyzed, and attempts were made to reduce any potential
bias present in this study in order to achieve more
homogeneous patient groups.
Conclusions
The application of an interstitial implantation
brachytherapy technique that uses 3D treatment plan
system (PLATO BPS 14.2) was evaluated for the treat-
ment of stage T2b NPC patients. Although the techni-
que is relatively complicated, it can be performed with
well tolerated complications. Overall, the administra-
tion of interstitial 3D-HDR-BT achieved excellent local
control for stage T2b NPC patients as a result of
improved target coverage and conformality of the
radiation dose applied. However, additional prospec-
tive, randomized studies are needed to confirm the
r e s u l t so ft h i ss t u d y .
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